HRP920192B1 - Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin - Google Patents

Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin

Info

Publication number: HRP920192B1
Authority: HR; Croatia
Prior art keywords: diseases; influencing; pharmaceutical composition; accompanying; chronic pain
Prior art date: 1991-07-24

Application number

HR920192A

Other languages

English (en)

Inventor

Joszef Beres

Joszef Beres Jr

Original Assignee

Beres Export Imp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-24

Filing date

1992-06-26

Publication date

2000-06-30

1992-06-26 Application filed by Beres Export Imp filed Critical Beres Export Imp

1994-04-30 Publication of HRP920192A2 publication Critical patent/HRP920192A2/hr

2000-06-30 Publication of HRP920192B1 publication Critical patent/HRP920192B1/xx

Links

201000010099 disease Diseases 0.000 title abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
201000003883 Cystic fibrosis Diseases 0.000 title abstract 2
208000022371 chronic pain syndrome Diseases 0.000 title abstract 2
230000003412 degenerative effect Effects 0.000 title abstract 2
230000003137 locomotive effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
210000000865 mononuclear phagocyte system Anatomy 0.000 title 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
230000002378 acidificating effect Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
230000007935 neutral effect Effects 0.000 abstract 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 abstract 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
239000001358 L(+)-tartaric acid Substances 0.000 abstract 1
235000011002 L(+)-tartaric acid Nutrition 0.000 abstract 1
FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 abstract 1
239000002211 L-ascorbic acid Substances 0.000 abstract 1
235000000069 L-ascorbic acid Nutrition 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 abstract 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
239000012736 aqueous medium Substances 0.000 abstract 1
239000012752 auxiliary agent Substances 0.000 abstract 1
229910052796 boron Inorganic materials 0.000 abstract 1
239000010941 cobalt Substances 0.000 abstract 1
229910017052 cobalt Inorganic materials 0.000 abstract 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 1
229910052802 copper Inorganic materials 0.000 abstract 1
239000010949 copper Substances 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229910052750 molybdenum Inorganic materials 0.000 abstract 1
239000011733 molybdenum Substances 0.000 abstract 1
229910052759 nickel Inorganic materials 0.000 abstract 1
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 abstract 1
229940074439 potassium sodium tartrate Drugs 0.000 abstract 1
239000002244 precipitate Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
235000011006 sodium potassium tartrate Nutrition 0.000 abstract 1
239000001384 succinic acid Substances 0.000 abstract 1
229910052720 vanadium Inorganic materials 0.000 abstract 1
GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Electrotherapy Devices (AREA)
Circuits Of Receivers In General (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)

HR920192A 1991-07-24 1992-06-26 Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin HRP920192B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU912492A HU207799B (en)	1991-07-24	1991-07-24	Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (2)

Publication Number	Publication Date
HRP920192A2 HRP920192A2 (hr)	1994-04-30
HRP920192B1 true HRP920192B1 (en)	2000-06-30

Family

ID=10959658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR920192A HRP920192B1 (en)	1991-07-24	1992-06-26	Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin

Country Status (18)

Country	Link
US (2)	US5312629A (ja)
EP (1)	EP0524633B1 (ja)
JP (1)	JP2673852B2 (ja)
KR (1)	KR100234855B1 (ja)
AT (1)	ATE178213T1 (ja)
BG (1)	BG61250B1 (ja)
CA (1)	CA2074639C (ja)
CZ (1)	CZ281672B6 (ja)
DE (1)	DE69228777T2 (ja)
FI (1)	FI923364A7 (ja)
HR (1)	HRP920192B1 (ja)
HU (1)	HU207799B (ja)
PL (1)	PL169684B1 (ja)
RO (1)	RO109505B1 (ja)
RU (1)	RU2093160C1 (ja)
SI (1)	SI9200155A (ja)
SK (1)	SK278944B6 (ja)
YU (1)	YU48243B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5871779A (en) *	1994-01-18	1999-02-16	Mount Sinai Hospital Corporation	Treatment of arthropathies with vanadate compounds or analogues thereof
US5843481A (en) *	1994-01-18	1998-12-01	Mount Sinai Hospital Corporation	Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
GB9416768D0 (en) *	1994-08-18	1994-10-12	Nycomed Innovation Ab	Compositions
WO1996005867A2 (en) *	1994-08-18	1996-02-29	Nycomed Imaging A/S	Compositions
GB9416767D0 (en) *	1994-08-18	1994-10-12	Nycomed Innovation Ab	Compositions
US5863519A (en) *	1994-08-18	1999-01-26	Nycomed Imaging As	Composition and method of MRI using both a positive and a negative contrast agent
FR2740342B1 (fr) *	1995-10-26	1997-12-19	Oreal	Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) *	1999-05-05	2000-03-10	Дубинина Лариса Васильевна	Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) *	2000-09-29	2003-09-11	Steiner Gregory Gene	Fluoride compositions and uses thereof
US6638431B2 (en) *	2001-05-03	2003-10-28	Mainstream Engineering Corporation	Formulation and method for treating wetted surface elements in climate control systems
KR20050018250A (ko) *	2003-08-14	2005-02-23	한영주	복합생약 조성물을 함유하는 항암활성을 갖는 조성물
KR100889994B1 (ko) *	2003-08-14	2009-03-24	한영미	녹반을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) *	2004-12-22	2006-06-22	Bortz Jonathan D	Compositions including iron
WO2006130027A1 (en) *	2005-05-31	2006-12-07	Santos Ma Joyce Bedelia B	Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
WO2006130839A1 (en) *	2005-06-02	2006-12-07	U.S. Borax Inc.	Prevention and treatment of osteochondrosis in animals and humans
RU2009125565A (ru) *	2006-12-06	2011-01-20	Ю. Эс. Боракс Инк. (Us)	Композиции корма для животных
EP1949894B1 (en) *	2007-01-25	2016-06-29	Roche Diagnostics GmbH	Enhancement of vanadium-containing phosphatase inhibitors by polyols
US8008035B2 (en)	2007-01-25	2011-08-30	Roche Diagnostics Operations, Inc.	Enhancement of vanadium-containing phosphatase inhibitors
US10634385B2 (en)	2009-09-03	2020-04-28	Ademco Inc.	Heat balancing system
WO2013167298A1 (en)	2012-05-11	2013-11-14	Kael-Gemvax Co., Ltd.	Anti-inflammatory peptides and composition comprising the same
ES2981865T3 (es)	2012-07-11	2024-10-10	Gemvax & Kael Co Ltd	Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
RU2677277C2 (ru)	2013-06-07	2019-01-16	Джемвакс Энд Каэл Ко., Лтд.	Биологические маркеры, которые могут быть использованы в иммунотерапии рака
JP6495899B2 (ja)	2013-06-21	2019-04-03	ジェムバックスアンドカエルカンパニー，リミティド	ホルモン分泌調節剤、及びそれを含む組成物
KR102314231B1 (ko)	2013-12-17	2021-10-19	주식회사 젬백스앤카엘	전립선 암 치료용 조성물
WO2015126265A1 (en) *	2014-02-18	2015-08-27	Santos Joyce Bedelia B	Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
WO2015156649A1 (ko)	2014-04-11	2015-10-15	주식회사 젬백스앤카엘	섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6466971B2 (ja)	2014-04-30	2019-02-06	ジェムバックスアンドカエルカンパニー，リミティド	臓器、組織又は細胞移植用組成物、キット及び移植方法
KR102413243B1 (ko)	2014-12-23	2022-06-27	주식회사 젬백스앤카엘	안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko)	2015-02-27	2024-02-14	주식회사 젬백스앤카엘	청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
KR102638286B1 (ko)	2015-07-02	2024-02-20	주식회사 젬백스앤카엘	항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
US10898540B2 (en)	2016-04-07	2021-01-26	Gem Vax & KAEL Co., Ltd.	Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CN114177196B (zh) *	2020-09-14	2025-12-05	深圳市方升泰医药科技有限公司	钒化合物用于治疗疼痛的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2022998B (en) *	1978-06-14	1982-09-08	Beres J	Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) *	1978-06-26	1980-01-12	Peresu Yozefu	Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

1991
- 1991-07-24 HU HU912492A patent/HU207799B/hu unknown
- 1991-07-26 US US07/736,314 patent/US5312629A/en not_active Expired - Fee Related
1992
- 1992-06-26 HR HR920192A patent/HRP920192B1/xx not_active IP Right Cessation
- 1992-07-21 PL PL92295352A patent/PL169684B1/pl not_active IP Right Cessation
- 1992-07-22 RO RO92-01006A patent/RO109505B1/ro unknown
- 1992-07-23 RU SU925052277A patent/RU2093160C1/ru active
- 1992-07-24 AT AT92112643T patent/ATE178213T1/de not_active IP Right Cessation
- 1992-07-24 SK SK2326-92A patent/SK278944B6/sk unknown
- 1992-07-24 BG BG96686A patent/BG61250B1/bg unknown
- 1992-07-24 EP EP92112643A patent/EP0524633B1/en not_active Expired - Lifetime
- 1992-07-24 JP JP4217451A patent/JP2673852B2/ja not_active Expired - Fee Related
- 1992-07-24 CZ CS922326A patent/CZ281672B6/cs unknown
- 1992-07-24 KR KR1019920013264A patent/KR100234855B1/ko not_active Expired - Fee Related
- 1992-07-24 CA CA002074639A patent/CA2074639C/en not_active Expired - Fee Related
- 1992-07-24 FI FI923364A patent/FI923364A7/fi not_active Application Discontinuation
- 1992-07-24 SI SI19929200155A patent/SI9200155A/sl unknown
- 1992-07-24 DE DE69228777T patent/DE69228777T2/de not_active Expired - Fee Related
- 1992-09-02 YU YU81092A patent/YU48243B/sh unknown
1993
- 1993-11-12 US US08/152,052 patent/US5405620A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0524633A3 (en)	1993-07-28
BG96686A (bg)	1993-12-24
JP2673852B2 (ja)	1997-11-05
FI923364A0 (fi)	1992-07-24
ATE178213T1 (de)	1999-04-15
YU81092A (sr)	1996-01-09
CA2074639A1 (en)	1993-01-25
CZ232692A3 (en)	1993-02-17
RU2093160C1 (ru)	1997-10-20
US5312629A (en)	1994-05-17
YU48243B (sh)	1997-08-22
PL169684B1 (pl)	1996-08-30
CZ281672B6 (cs)	1996-12-11
HU207799B (en)	1993-06-28
US5405620A (en)	1995-04-11
RO109505B1 (ro)	1995-03-30
CA2074639C (en)	1996-01-09
EP0524633A2 (en)	1993-01-27
HUT61475A (en)	1993-01-28
KR100234855B1 (ko)	1999-12-15
PL295352A1 (en)	1993-02-22
SK278944B6 (sk)	1998-05-06
HRP920192A2 (hr)	1994-04-30
BG61250B1 (bg)	1997-04-30
FI923364A7 (fi)	1993-01-25
SI9200155A (en)	1993-03-31
KR930001915A (ko)	1993-02-22
JPH06227992A (ja)	1994-08-16
DE69228777T2 (de)	1999-10-21
HU912492D0 (en)	1991-12-30
EP0524633B1 (en)	1999-03-31
SK232692A3 (en)	1995-06-07
DE69228777D1 (de)	1999-05-06

Legal Events

Date	Code	Title	Description
1994-04-30	A1OB	Publication of a patent application
1994-10-10	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2000-06-30	B1PR	Patent granted
2011-06-23	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20110623 Year of fee payment: 20
2012-12-27	PB20	Patent expired after termination of 20 years	Effective date: 20120627

Publication	Publication Date	Title
HRP920192B1 (en)	2000-06-30	Pharmaceutical composition suitable for influencing the reticuloendothelial system and for treating mucoviscidosis and chronic pain syndromes deriving from degenerative locomotor diseases or accompanying the diseases of tumorous origin
EP0954514B1 (en)	2014-12-31	Fertilizer compositions including chelated metal ions
AU8110098A (en)	1998-12-30	A process for the preparation of macrocyclic chelants and the chelates thereof with paramagnetic metal ions
CA2263379A1 (en)	1998-02-19	Method for iron delivery to a patient by transfer from dialysate
DE3567463D1 (en)	1989-02-16	4-dimethylamino-1-hydroxybutane-1,1-diphosphonic acid, its water soluble salts, process for their preparation and its use
GR860023B (en)	1986-05-06	Method for the preparation of peptidic derivatives with a azote polycyclic structure
AU4950096A (en)	1996-10-02	Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
CA2020858A1 (en)	1991-01-15	Water treatment agent and water treatment method for boiler
NZ334854A (en)	2001-01-26	Foliar fertilisers including trace element compounds
ZA947199B (en)	1995-09-18	Pre-rinse for phosphating metal surfaces
AU657748B2 (en)	1995-03-23	Improvements in or relating to method of connecting a manganese steel part to another carbon steel part and assembly thus obtained
ES8500226A1 (es)	1984-10-01	Un procedimiento de preparacion de imino-2-pirrolidinas.
IL142292A0 (en)	2002-03-10	Ion exchange tumor targeting
WO1999039707A8 (en)	1999-10-21	Metal-thiols as immunomodulating agents
ES8300066A1 (es)	1982-10-01	Procedimiento para la obtencion de un nuevo antiacido gas- trico
AU2170701A (en)	2001-07-16	Brightening/passivating metal surfaces without hazard from emissions of oxides of nitrogen
AU5214900A (en)	2000-12-18	Pressed products of non-caking salt
CA2255664A1 (en)	1997-12-11	Selenophene anti-tumor agents
EP0805211A3 (en)	1998-12-02	Process for producing optically active aminopolycarboxylic acid
IE852531L (en)	1986-04-16	Metal complexes of bis-indoles
ES2044777A1 (es)	1994-01-01	Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
HUP9801499A2 (hu)	2000-04-28	Metasztázisgátló gyógyászati készítmény és eljárás ennek előállítására
Bennett	1987	Hypercalcemia of Malignancy
GB1216388A (en)	1970-12-23	A process for purifying amino acids
GB9008724D0 (en)	1990-06-13	Chemical compounds